AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04410094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.
Study NCT04410094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules will be administered orally.
Study NCT04410094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules will be administered orally.
Study NCT00580723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRK 124
Description: Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
Study NCT04995575 — intervention group
Intervention type: PROCEDURE
Intervention: collection of the biopsy, blood samples
Description: for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples
Study NCT00556998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
Study NCT03997526 — intervention group
Intervention type: DEVICE
Intervention: 3C Patch
Description: A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
Study NCT03707301 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
Study NCT01982123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
Study NCT01982123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
Study NCT01982123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Albumin Aggregated
Description: Undergo 99mTc-MAA SPECT/CT
Study NCT01982123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m DTPA
Description: Undergo 99mTc-DTPA SPECT/CT
Study NCT02426515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm® cooling device and face mask
Description: Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
Study NCT00880698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq
Description: 2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose
Study NCT00880698 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL solution
Study NCT01112397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480
Description: continuous daily oral capsule
Study NCT03591926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04646
Description: Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week.
Study NCT00675909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Intranasal midazolam
Description: Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg.
Study NCT00675909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Buccal Midazolam
Description: 0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth.
Study NCT00675909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: oral midazolam 0.5mg/kg
Study NCT03811444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haemolance Plus safety lancet
Description: Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
Study NCT03811444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance safety lancet
Description: Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
Study NCT03811444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSafe Solo safety lancet
Description: MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
Study NCT02392130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Study NCT02392130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 130852A gel 1%
Study NCT02392130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 130852A placebo gel
Study NCT02727907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-033 (interferon beta 1a)
Description: Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
Study NCT02727907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif (interferon beta 1a)
Description: Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
Study NCT02727907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
Study NCT02006914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Chromium Picolinate
Description: Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
Study NCT00806039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Renal Involvement
Description: Renal Consultation
Study NCT01696370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Trimetazidine 20mg three times per day for 3 months
Study NCT01696370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: one capsule three times per day for 3 months
Study NCT01451489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: FK506:0.05-0.1mg/kg/d
Study NCT01451489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
Study NCT00189839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Immunosuppression
Study NCT00189839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Immunosuppression
Study NCT01528930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: 500 mg, once daily for 2 years
Study NCT02339246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf vs Envarsus XR vs Astagraf XL
Description: prograf vs Envarsus XR vs Astagraf XL
Study NCT02339246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf vs Astagraf XL vs Envarsus XR
Description: Prograf vs Astagraf XL vs Envarsus XR
Study NCT02544126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Self-Management Resource Training for Mental Health
Description: eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
Study NCT02544126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screen-based health education
Description: Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
Study NCT00567853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of the MEMO 3D Annuloplasty Ring
Description: Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
Study NCT02120066 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy for submacular hemorrhage
Study NCT02120066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: subretinal injection of tissue-plasminogen activator
Study NCT02722226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: High fidelity simulation based sedation learning program
Study NCT02722226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway management
Description: Workshop on using airway management and oxygenation devices.
Study NCT02722226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis resource management
Description: Learning crisis resource management principles
Study NCT01509235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
Study NCT01509235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
Study NCT01398371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of digoxin
Description: Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
Study NCT01398371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
Study NCT02673918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based upper-body rehabilitation with online support
Description: Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes.
Study NCT02021942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR
Description: SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
Study NCT00818792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent
Description: Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
Study NCT02604849 — intervention group
Intervention type: DRUG
Intervention: Neomycin
Study NCT00004144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study NCT00004144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00577122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone progesterone acetate (MPA)
Description: 1000 mg po daily
Study NCT00577122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone with Cyclophosphamide + Methotrexate
Description: Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
Study NCT02604849 — intervention group
Intervention type: DRUG
Intervention: Streptomycin
Study NCT02604849 — intervention group
Intervention type: DRUG
Intervention: Gentamicins
Study NCT05184530 — intervention group
Intervention type: DRUG
Intervention: Evolocumab 140 MG/ML
Description: 140 mg per two weeks, subcutaneous injection
Study NCT03359174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 2.5 mg
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Rosuvastatin
Study NCT02741245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rosuvastatin
Study NCT02401347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Participants receive Talazoparib tosylate at 1 mg by mouth daily.
Study NCT01685567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MICHI NPS+f
Description: Cerebral protection with carotid flow reversal
Study NCT02591108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Block Aid
Description: Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
Study NCT02591108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Block Aid
Description: Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
Study NCT02591108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Microstim Plus
Description: A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
Study NCT02591108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care: Microstim Plus
Description: A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
Study NCT03291483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
Study NCT03291483 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: plyometric training
Description: Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
Study NCT03291483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
Study NCT02354534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Study NCT05357716 — intervention group
Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
Study NCT05357716 — intervention group
Intervention type: DEVICE
Intervention: Event Recorder
Description: A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
Study NCT05357716 — intervention group
Intervention type: DEVICE
Intervention: Holter Monitor
Description: A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
Study NCT03679728 — intervention group
Intervention type: BEHAVIORAL
Intervention: First trimester
Description: Analysis of sensorimotor outcomes
Study NCT03679728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Second trimester
Description: Analysis of sensorimotor outcomes
Study NCT02982564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program Low Intensity
Description: This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
Study NCT02982564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program Moderate Intensity
Description: This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
Study NCT02747186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intraoral maxillary field block
Study NCT01363089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
Study NCT01363089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Description: Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
Study NCT03076138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene-activated matrix (OCP + plasmid DNA with VEGF gene)
Description: Bone grafting procedure with investigated medical device
Study NCT01209897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation booklet
Study NCT01209897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation booklet